The ALLG is an Australian not-for-profit, public unlisted company limited by guarantee and is a registered charity.

ALLG Board of Management

The ALLG is governed on behalf of members by a Board of Management in accordance with the ALLG Constitution. Subject to the exercise by the Board of the powers contained in the ALLG Constitution, the Board manages the company and directs the affairs of the company. Current Board members are:

David Fagan

LLB, LLM, GAICD
Chair of the Board

Mr David Fagan was appointed to the ALLG Board as Chair and Director on 15 December 2025.

Colin Allen

MBA (John Hopkins University, USA)

Colin was elected to the ALLG Board as a Director in late 2022 with aims to utilise his skills, experience and networks; and champion donor-centric experiences to achieve the ALLG’s philanthropic goals that will progress the mission for better treatments.

Professor

Peter Browett

BMedSci, MBChB, FRACP, FRCPA, Director

Peter has been an active member of the Company since April 1997. He currently chairs the Safety and Data Monitoring Committee (SDMC).

Professor

Mark Hertzberg

MBBS PhD FRACP FRCPA
Director

Mark Hertzberg has been an active member of the ALLG for 27 years, previously serving as Chair of the Scientific Advisory Committee and High Grade Lymphoma Group at the ALLG from 2010 to 2017.

Zed Ivankovic

Zed Ivankovic is a corporate affairs and marketing executive with 20 years of leadership experience across finance, telecommunications, manufacturing, logistics, and government.

Zed Ivankovic was elected to the Board in May 2025.

Joy Linton

Joy Linton was elected to the Board July 2026. Joy has over 35 years’ experience as a strategic and finance global executive in businesses across healthcare, insurance and fast-moving consumer goods.

Joy Linton was elected to the Board mid July 2026. Joy has over 35 years’ experience as a strategic and finance global executive in businesses across healthcare, insurance and fast-moving consumer goods.

Alastair Lomas

Originally from the UK, Alastair is a Regional CFO with more than 25 years’ experience partnering CEOs and executive leadership teams across pharmaceuticals, biotech and healthcare, including senior finance roles at Amgen, Vertex Pharmaceuticals and Alexion.

Professor

Judith Trotman

BHB, MBChB, FRACP, FRCPA, PostGrad Cert Clin Res (Oncology)
Director

Judith has been a prominent ALLG Member for more then 20 years and was a Scientific Advisory Committee (SAC) representative member from 2014 – 2019. She was appointed as the Chair of the SAC in October 2022.

Professor

Deborah White

PhD FFSc (RCPA)

Deborah was elected to the Board in March 2023. She has been an active member of the ALLG since 2002. Deborah is the Precision Medicine Theme Co-Leader at the South Australian Health and Medical Research Institute (SAHMRI) in Adelaide, and Group Leader of the Acute Lymphoblastic Leukaemia Genomics and Functional Genomics Research Group (Australian Lead Centre).